Trial site
CHU De Martinique
Fort De France Cedex, 97261, FranceNot linked to an institution yet
- 16running trials
- 2closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 24 trials
- Status
- Recruiting10 trials
- Not yet recruiting4 trials
- Active, not recruiting2 trials
- Completed2 trials
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris3 trials
- UNICANCER3 trials
- Eidos Therapeutics, a BridgeBio company2 trials
- Alnylam Pharmaceuticals1 trial
- Assistance Publique Hopitaux De Paris1 trial
- and 8 more
Running trials
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Not yet recruiting
Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial
2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
MODULO
NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source
Recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· Phase 3· UNICANCER· Source
Recruiting
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction
2023-508798-94-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Recruiting
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
NCT04702256· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Recruiting
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT04290663· Phase 3· Centre Francois Baclesse· Source
Active, not recruiting
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203· Phase 3· UNICANCER· Source
Recruiting
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Completed
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
NCT03255434· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source
Active, not recruiting
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error